Annals of Surgical Oncology

, Volume 16, Issue 9, pp 2609–2616

High Recurrent Rate of Multicentric Papillary Thyroid Carcinoma

  • Jen-Der Lin
  • Tzu-Chieh Chao
  • Chuen Hsueh
  • Sheng-Fong Kuo
Endocrine Tumors

DOI: 10.1245/s10434-009-0565-7

Cite this article as:
Lin, JD., Chao, TC., Hsueh, C. et al. Ann Surg Oncol (2009) 16: 2609. doi:10.1245/s10434-009-0565-7

Abstract

Background

Multicentric papillary thyroid carcinoma (PTC) is not unusual in patients with PTC. However, its clinical features concerning cancer recurrence and mortality are not well described.

Methods

A total of 1682 PTC patients at a single institution who underwent total thyroidectomy were retrospectively reviewed; the mean follow-up period was 7.7 ± 0.1 years. Postoperative radioactive iodide ablation for thyroid remnant was performed after surgery for most patients.

Results

Of all the PTC cases reviewed, 337 cases (20.0%) were categorized as multicentric PTC. Compared with patients with unifocal PTC, multicentric PTC patients demonstrated older age, advanced TNM staging, and higher recurrence. A higher recurrence rate for multicentric PTC (20.2%) was observed compared with that for unifocal PTC; 45.8% of multicentric PTC cases with ≥ 5 foci experienced cancer recurrence. Mean tumor size of the largest nodule in patients with multicentric PTC was significantly smaller than that found in unifocal PTC. Patients with multicentric papillary microcarcinoma (≤1 cm) had higher recurrence rate and cancer mortality than those with unifocal papillary microcarcinoma. Of the recurrent multicentric PTC cases, 52.9% were persistent or diagnosed within the first year of thyroidectomy and had a cancer-related mortality of 27.8%. The 5-, 10-, and 20-year survival rates of multicentric PTC patients were 97.7%, 94.4%, and 84.7%, respectively, which were not statistically different from those of unifocal PTC patients.

Conclusions

Multicentric PTC warrant postoperative adjuvant therapy and close surveillance within the first year. Patients with multicentric papillary thyroid microcarcinoma need to be treated as high-risk patients.

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Jen-Der Lin
    • 1
  • Tzu-Chieh Chao
    • 2
  • Chuen Hsueh
    • 3
  • Sheng-Fong Kuo
    • 1
  1. 1.Division of Endocrinology and Metabolism, Department of Internal MedicineChang Gung Memorial Hospital, Chang Gung UniversityKweishan County, Taoyuan HsienTaiwan R.O.C
  2. 2.Department of General SurgeryChang Gung Memorial Hospital, Chang Gung UniversityKweishan County, Taoyuan HsienTaiwan R.O.C
  3. 3.Department of PathologyChang Gung Memorial Hospital, Chang Gung UniversityKweishan County, Taoyuan HsienTaiwan R.O.C